FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:990-992 April 11, 1996 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Philip, T. Related Article by Philip, T.

To the Editor: In the report by Philip et al.¹ (Dec. 7 issue), there are several shortcomings in the Parma Group's comparison of high-dose chemotherapy and autologous bone marrow transplantation with conventional salvage chemotherapy for patients with relapsed lymphoma.

First, the authors state that the base-line characteristics of the two study groups were similar. According to their Table 1, however, there were consistently more patients with adverse prognostic factors in the conventional-treatment group than in the transplantation group: 30 percent versus 20 percent with high-grade histologic features, 17 percent versus 9 percent with a second relapse, 24 percent versus 16 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.